Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 9Terminated 3Active not recruiting 3Recruiting 2Withdrawn 1Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 1Lymphoid 1

Conditions

Prostatic Neoplasms 36Lymphoma, Large B-Cell, Diffuse 16Lymphoma 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Burkitt Lymphoma 7Neoplasms 6Multiple Myeloma 6Lymphoma, Non-Hodgkin 6Lymphoma, Follicular 6Leukemia 6Lymphoma, B-Cell 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Recurrence 3Neoplasm Metastasis 3Lymphoma, T-Cell 3Lymphoma, B-Cell, Marginal Zone 3Hodgkin Disease 3Waldenstrom Macroglobulinemia 2Pain 2Neoplasms by Histologic Type 2Myelodysplastic Syndromes 2Lymphatic Diseases 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Neoplasms 2Hematologic Diseases 2Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumours 1Sezary Syndrome 1

Interventions

Dexamethasone 29Cyclophosphamide 21Rituximab 17Cytarabine 16Bortezomib 13Gemcitabine 12fludarabine 11Methotrexate 11Lenalidomide 10Filgrastim 10Vincristine 9Etoposide 9pomalidomide 8pembrolizumab 8Paclitaxel 8Azacitidine 8venetoclax 7carfilzomib 7Doxorubicin 7Docetaxel 7Cyclosporine 7Calcium Dobesilate 7Antilymphocyte Serum 7fludarabine phosphate 6Topotecan 6Temozolomide 6Radiotherapy 6Peripheral Blood Stem Cell Transplantation 6Mitoxantrone 6daratumumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Recurrence × Prednisone × Clear all
NCT01186328 2024-02-01

EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

Therapeutic Advances in Childhood Leukemia Consortium

Phase 1 Terminated
6 enrolled 11 charts
LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02294357 2023-11-01

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Oncotherapeutics

Phase 2 Terminated
45 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT01116128 2011-06-14

D-MP

Fondazione EMN Italy Onlus

Phase 2 Terminated
8 enrolled
Plasma cell

Recurrence, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡